A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment
Condition(s) studied
Investigational drug(s) / intervention(s)
Prifetrastat: Prifetrastat administered by mouth as a single dose.
Study summary
The primary purpose of this study is to understand how the body processes the study medicine, called prifetrastat, in people with renal impairment compared to healthy people with normal kidney function. Renal impairment means that a person has worse kidney function than normal. The study will also look at the safety and tolerability of prifetrastat in people with renal impairment compared to healthy people with normal kidney function.
This study is seeking participants who:
* Have moderate or severe renal impairment or
* Healthy people with normal kidney function
All participants in this study will receive a single dose of prifetrastat. The study medicine will be given by mouth at the study clinic. We will compare experiences of people with renal impairment and healthy people with normal kidney function.
Participants will take part in this study for about 2 months. During this time, they will stay at the study clinic for 8 to 16 days.
Eligibility
Primary outcome measure(s)
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prifetrastat — Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
- Maximum Observed Plasma Concentration (Cmax) of Prifetrastat — Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| Floridian Clinical Research | Miami Lakes | Florida | |
| Genesis Clinical Research, LLC | Tampa | Florida | |
| Nucleus Network Minneapolis | Saint Paul | Minnesota |
More Pfizer trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07933848 on ClinicalTrials.gov ↗ ← All trials in the USA